Sign up to save your podcasts
Or
Share Advancements in Radionuclide Drug Conjugates and Key Appointment at Avantor, Inc.
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Advancements in Radionuclide Drug Conjugates and Key Appointment at Avantor, Inc.
The progress in Radionuclide Drug Conjugates (RDCs) research for cancer management is highlighted, showcasing precision tumor targeting and personalized therapy. Prof. Hongyun Wang emphasizes RDCs' potential for accurate diagnoses and effective treatment. Meanwhile, Avantor, Inc. appoints Gladys Wang as Vice President for Bioprocessing Commercial in Asia, Middle East, and Africa, aiming to drive business expansion and enhance customer success in the region.
View all episodes
By NewsRampThe progress in Radionuclide Drug Conjugates (RDCs) research for cancer management is highlighted, showcasing precision tumor targeting and personalized therapy. Prof. Hongyun Wang emphasizes RDCs' potential for accurate diagnoses and effective treatment. Meanwhile, Avantor, Inc. appoints Gladys Wang as Vice President for Bioprocessing Commercial in Asia, Middle East, and Africa, aiming to drive business expansion and enhance customer success in the region.